italian diffuse/ multivessel disease absorb prospective registry under the auspices of
DESCRIPTION
Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of Società Italiana di Cardiologia Invasive-GISE. IT - DISAPPEARS. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/1.jpg)
Italian Diffuse/Multivessel Disease
ABSORB Prospective Registry
under the auspices of
Società Italiana di Cardiologia Invasive-GISE
![Page 2: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/2.jpg)
2
IT - DISAPPEARSObjective: Investigate short-and long-term clinical performance of Absorb in MVD (at least 2≠ epicardial vessels) or long single vessel disease (>24mm)
Co-PI: Dr. F Bedogni & Dr. A S Petronio
Clinical follow-up
30dy 6mo 1yr 2yr 3yr 4yr 5yr
Primary Endpoint
Absorb
1000 Patients 50 Italian centres
Steering committee: Prof. Bartorelli, Prof. Indolfi, Prof. Richibini, Prof.Tamburino, Dr. Tomai, De. De Carlo, Dr Biondi Zoccai and Dr. Testa
![Page 3: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/3.jpg)
Principal Investigator:
Prof. Anna Sonia Petronio
Dr. Francesco Bedogni
Protocol Authors:
Dr. LucaTesta
Dr. Marco De Carlo
Dr. Giuseppe Biondi-Zoccai
Steering committee:
Prof. Bartorelli
Prof. Indolfi
Prof. Richibini
Prof. Tamburino
DSB and CEC Coordinator: Dr. Tomai
e-CRF : Airon Telematica
CRO: GB Pharma
![Page 4: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/4.jpg)
AIM OF THE STUDY: to investigate the procedural and the long-term clinical performance of the ABSORB technology in patients with:
1) multivessel disease (at least two significant stenosis in 2 different coronary arteries)
2) long (>24 mm) single vessel disease.
![Page 5: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/5.jpg)
•PRIMARY ENDPOINT: the cumulative hierarchical incidence of MACE defined as:
– cardiac death, – non-fatal target vessel myocardial infarction (MI), or – clinically driven target lesion revascularization (TLR).
•SECONDARY ENDPOINTS: – All causes mortality, – clinically driven TVR, – any revascularisation (non TLR, non TVR) – and ARC-defined stent thrombosis, at any time point.
![Page 6: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/6.jpg)
• STUDY DESIGN: multicenter (50 centers across the Italian territory aiming at 20 cases per center. Ad interim evaluation September 2014), prospective observational registry aiming to enroll a population of 1000 patients.
• STUDY DURATION: We project 12 months for recruitment, 5 year follow-up duration after last patient in the registry.
• CLINICAL FOLLOW-UP PLAN: 30 days, 6 months, 1 year, and then yearly up to 5 years after the index procedure.
![Page 7: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/7.jpg)
INCLUSION CRITERIA:
Indication to PCI for MVD or long (>24 mm) single vessel disease following:
• Stable angina or evidence of myocardial ischemia with stress echocardiography/myocardial SPECT/exercise test, or
• Unstable angina / non ST-elevation myocardial infarction• ST-elevation myocardial infarction with de novo culprit lesion.
![Page 8: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/8.jpg)
EXCLUSION CRITERIA:
• Known intolerance to any of the device components• Contraindication to DAPT• Lesion in a SVG• Lesion to LIMA • Unprotected LM stenosis• Woman with childbearing potential• Age < 18y/o• Concomitant indication to open heart surgery• Inability to provide written informed consent• In-stent restenosis• Enrolment in other studies\registries in the last 30 days
![Page 9: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/9.jpg)
Procedure
• Appropriate anticoagulation according to standard hospital practice. • QCA analysis is recommended for correct sizing.
• IVUS, VH-IVUS, OCT techniques are encouraged (subgroup analysis).
• Patients with MVD may be treated with ABSORB in one vessel and with a conventional BMS/DES in another vessel (“hybrid population”, subgroup analysis).
![Page 10: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/10.jpg)
MVD “hybrid population”
A “hybrid BVS-other DES” approach is acceptable under the following situations:
for patients with two vessel disease at least 1 lesion must be >24 mm and must be treated with the BVS;
for patients with 3 vessel disease provided that 2 vessels are treated with BVSThe use of a everolimus DES is recommended in case of hybrid treatment
![Page 11: Italian Diffuse/ Multivessel Disease ABSORB Prospective Registry under the auspices of](https://reader035.vdocument.in/reader035/viewer/2022070418/568157f2550346895dc56cab/html5/thumbnails/11.jpg)
Follow-up
Clinical Follow-upTelephone contact or office visits per the following schedule: • 30 days: office visit is encouraged• 6 months: office visit is encouraged• 1 year, and then yearly up to 5 years after the index procedure: office visit is
encouraged.
Angiographic follow up• The angiographic follow up will be clinically driven. • Patients undergoing angio follow up and IVUS or OCT follow up will be included in
subgroup analysis.